Featured Research

from universities, journals, and other organizations

Clonal evolution in maxillary sinus carcinoma

Date:
September 29, 2012
Source:
The Translational Genomics Research Institute
Summary:
Knowing how tumors evolve can lead to new treatments that could help prevent cancer from recurring, according to researchers. They have tracked several years of tumor evolution in a 47-year-old male patient with maxillary sinus carcinoma, a rare cancer of the sinus cavities beneath the cheeks that often requires surgical removal that is disfiguring.

Knowing how tumors evolve can lead to new treatments that could help prevent cancer from recurring, according to a study published September 29 by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare.

TGen researchers tracked several years of tumor evolution in a 47-year-old male patient with maxillary sinus carcinoma (MSC), a rare cancer of the sinus cavities beneath the cheeks that often requires surgical removal that is disfiguring. Fewer than half of MSC patients live more than 5 years after diagnosis.

"The ability to characterize clonal evolution of this rare cancer and identify its Achilles' heel can significantly impact treatment, leading to more personalized medicine," according to the study published in the journal PLOS ONE.

Clonal evolution refers to the often-rapid genetic changes that occur in cancer cells, which continually mutate and, thus, frequently resist anti-cancer drug compounds intended to destroy them.

"If we can understand the genomic basis of how this cancer evolves, perhaps we can find new treatments that could help improve the longevity and quality of life for patients," said Dr. Glen Weiss, Clinical Associate Professor at TGen, and Director of Thoracic Oncology at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with TGen. Dr. Weiss is one of the study's senior co-authors.

MSC represents nearly four of every five cases of paranasal sinus cancers, which grow rapidly and invade nearby tissues but also are usually slow to spread to distant sites. Patients usually die from a local recurrence of the tumor, even after aggressive treatment.

"This is the first report to study the clonal population of MSC arising in longitudinal samples from the same patient," the study said. "One of the aims of this study was to closely follow disease progression and the clonally evolving metastases for molecular profiling and accumulation of data for future use in development of personalized treatment."

The patient in the study received conventional treatment, which included surgical removal of his tumors, radiation therapy and chemotherapy, and participation in a clinical trial.

Over time, however, the cancer spread to his upper right lung, lower left lung, left kidney, brain and part of his intestine. He eventually was hospitalized, received hospice care and prior to passing away gave permission to have his cancer studied after death in a rapid autopsy research program.

"Because his cancer resumed growth despite several courses of systemic chemotherapy and radiation therapy, we speculated that acquired secondary genetic changes evolved with the evolution of resistance to these therapies," said Dr. Michael Barrett, Associate Professor in TGen's Clinical Translational Research Division, and the study's other senior co-author.

Analysis of his tumors following surgeries, biopsies and autopsy revealed several genetic aberrations, including multiple copies of a region on chromosome 4q, which includes the KIT gene. KIT is an oncogene, a gene with the potential to cause cancer, and is a potential treatment target.

The authors suggest the results provide a unique description of how the drug resistant cancer cells replicate and progress to metastatic MSC. Additional findings included the loss of the gene PKP4, which is associated with increased tumor size.

"These results show that molecular analyses of patient samples can add to the information about the tumor and help us in tracking back the progression of the disease," the authors concluded. "Identification of selected genetic changes, and the biological processes they regulate arising in primary MSC tumors, will advance individualizing therapy and improve the outcome of patients with rare cancers."

"These kinds of cutting-edge studies are made possible through the collaboration of major research and clinical practices, such as the partnership between TGen and Scottsdale Healthcare," said Dr. Mark Slater, Vice President of Research at Scottsdale Healthcare.

The authors remain particularly grateful to the patient and his family for their contribution to understanding more about this type of cancer and hope this dissemination of knowledge may help others.

Scottsdale Healthcare, Scottsdale Medical Imaging, and Sun Health Research Institute at Banner Healthcare contributed to this study, which was funded by the IBIS Foundation of Arizona and by the Scottsdale Healthcare Foundation.


Story Source:

The above story is based on materials provided by The Translational Genomics Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Arora S, Korn RL, Lenkiewicz E, Cherni I, Beach TG, et al. Clonal Evolution of a Case of Treatment Refractory Maxillary Sinus Carcinoma. PLoS ONE, 2012 DOI: 10.1371/journal.pone.0045614

Cite This Page:

The Translational Genomics Research Institute. "Clonal evolution in maxillary sinus carcinoma." ScienceDaily. ScienceDaily, 29 September 2012. <www.sciencedaily.com/releases/2012/09/120929140338.htm>.
The Translational Genomics Research Institute. (2012, September 29). Clonal evolution in maxillary sinus carcinoma. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2012/09/120929140338.htm
The Translational Genomics Research Institute. "Clonal evolution in maxillary sinus carcinoma." ScienceDaily. www.sciencedaily.com/releases/2012/09/120929140338.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Ebola Virus Threatens West Africa

Deadly Ebola Virus Threatens West Africa

AP (July 28, 2014) West African nations and international health organizations are working to contain the largest Ebola outbreak in history. It's one of the deadliest diseases known to man, but the CDC says it's unlikely to spread in the U.S. (July 28) Video provided by AP
Powered by NewsLook.com
$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Two Americans Contract Ebola in Liberia

Two Americans Contract Ebola in Liberia

Reuters - US Online Video (July 28, 2014) Two American aid workers in Liberia test positive for Ebola while working to combat the deadliest outbreak of the virus ever. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins